What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Pharmacogenomics Testing: A Guide to Personalized Medicine

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Pharmacogenomics Testing

What Is Pharmacogenomics?

Pharmacogenomics is the study of how an individual's genetic makeup influences their response to drugs. The field sits at the intersection of pharmacology and genomics, examining how inherited genetic variants affect drug metabolism, transport, and target engagement. Pharmacogenomics testing refers to the laboratory analysis of patient DNA to identify specific genetic variants that predict drug efficacy, toxicity risk, or required dose adjustments.

The fundamental premise is straightforward: patients with identical diagnoses can respond dramatically differently to the same medication at the same dose. For some, a standard dose of codeine produces adequate analgesia; for others, it causes life-threatening respiratory depression. For a subset, it does nothing at all. These differences are not random—they are largely attributable to germline genetic variation in genes encoding drug-metabolizing enzymes, transporters, and receptors.

The clinical goal of pharmacogenomics testing is to move prescribing from a trial-and-error paradigm toward a predictive one. Rather than starting all patients on a standard dose and adjusting based on observed response or toxicity, clinicians can use genetic information to select the right drug and dose from the outset. This approach is a cornerstone of what is broadly termed personalized or precision medicine.

Why Test for Genetic Variants?

Drug response is a complex phenotype influenced by age, sex, renal and hepatic function, concomitant medications, diet, and environmental factors. However, genetic variation accounts for an estimated 20% to 95% of interindividual variability in drug disposition and response, depending on the drug. For certain medications, such as the thiopurines used in leukemia treatment, genetic status is the single most important determinant of severe toxicity.

Testing for genetic variants serves several distinct purposes. First, it identifies patients at risk for adverse drug reactions before drug exposure. Second, it identifies patients who are unlikely to respond to a drug because they lack the enzymatic activity required to convert a prodrug to its active form. Third, it guides initial dose selection, particularly for drugs with narrow therapeutic indices. Fourth, it can explain prior poor response or unexpected toxicity, informing future prescribing decisions.

The clinical utility of pharmacogenomics testing is now supported by a substantial evidence base, and testing is increasingly integrated into routine clinical care in oncology, cardiology, psychiatry, and infectious disease. For a broader overview of the conceptual foundations, see the Pharmacogenomics Definition.

The Molecular Basis of Pharmacogenomics

Cytochrome P450 Enzymes

The cytochrome P450 (CYP) superfamily comprises membrane-bound hemoproteins that catalyze the oxidative metabolism of approximately 70% to 80% of all clinically used drugs. These enzymes are expressed predominantly in hepatocytes, with lower levels in the intestinal epithelium, kidney, and lung. The CYP enzymes relevant to pharmacogenomics belong primarily to families 1, 2, and 3, with CYP2D6, CYP2C19, CYP2C9, and CYP3A4/5 being the most clinically significant.

CYP2D6 is encoded by a highly polymorphic gene located on chromosome 22q13.2. More than 100 allelic variants have been described, and their functional consequences range from complete loss of activity to gene duplication resulting in ultrarapid metabolism. CYP2D6 metabolizes approximately 25% of all prescribed drugs, including many antidepressants, antipsychotics, opioids, and antiarrhythmics. The enzyme's substrates are typically lipophilic bases with a basic nitrogen atom that interacts with the heme iron.

CYP2C19 metabolizes proton pump inhibitors, clopidogrel, and several antidepressants. The *CYP2C19*2 allele (c.681G>A, rs4244285) creates a cryptic splice site that produces a truncated, nonfunctional protein. This variant is present in approximately 15% of Caucasians and 30% of East Asians. For clopidogrel, a prodrug requiring CYP2C19-mediated bioactivation, carriers of loss-of-function alleles have reduced active metabolite formation and higher rates of stent thrombosis after percutaneous coronary intervention.

CYP2C9 is responsible for the metabolism of warfarin, phenytoin, and many nonsteroidal anti-inflammatory drugs. The *CYP2C9*2 (c.430C>T, rs1799853) and *CYP2C9*3 (c.1075A>C, rs1057910) alleles reduce enzymatic activity by approximately 30% and 80%, respectively. These variants significantly affect warfarin dose requirements and bleeding risk.

The molecular mechanism underlying variant effects is diverse. Missense variants may alter substrate binding affinity, reduce enzyme stability, or disrupt heme coordination. Splice-site variants produce aberrant mRNA transcripts. Copy number variants, particularly in CYP2D6, result in gene duplication or deletion. Promoter variants can alter transcriptional regulation. The net effect is categorized into phenotype groups: poor metabolizer (PM), intermediate metabolizer (IM), normal metabolizer (NM), and ultrarapid metabolizer (UM).

Drug Transporters and Receptors

Beyond metabolizing enzymes, genetic variation in drug transporters and drug targets contributes substantially to interindividual drug response.

The ATP-binding cassette (ABC) transporter family includes P-glycoprotein (encoded by ABCB1, also known as MDR1), which functions as an efflux pump at the blood-brain barrier, intestinal epithelium, and renal tubules. The synonymous variant c.3435C>T (rs1045642) in ABCB1 has been associated with altered P-glycoprotein expression and function, affecting the disposition of digoxin, tacrolimus, and several antiretroviral drugs. Although the mechanistic basis of a synonymous variant's effect remains debated—it may affect mRNA stability or translation kinetics—the clinical associations are reproducible.

The solute carrier (SLC) family includes organic anion transporting polypeptides (OATPs) and organic cation transporters (OCTs). SLCO1B1 encodes OATP1B1, which mediates hepatic uptake of statins. The *SLCO1B1*5 allele (c.521T>C, rs4149056) reduces transport activity and is strongly associated with simvastatin-induced myopathy. In the SEARCH trial, carriers of the C allele had a 4.5-fold increased risk of myopathy compared with non-carriers.

Drug targets themselves are also polymorphic. The vitamin K epoxide reductase complex subunit 1 (VKORC1) is the target of warfarin. The promoter variant c.-1639G>A (rs9923231) reduces VKORC1 expression, decreasing the amount of warfarin required to achieve therapeutic anticoagulation. This variant explains approximately 25% of the interindividual variability in warfarin dose, comparable to the combined contribution of CYP2C9 variants.

Similarly, the beta-2 adrenergic receptor (ADRB2) harbors nonsynonymous variants that alter receptor downregulation and agonist response. The ADRB2 Arg16Gly variant (rs1042713) affects bronchodilator response in asthma patients, with Gly16 homozygotes showing reduced response to salbutamol compared with Arg16 homozygotes.

Types of Genetic Variants Detected

SNPs and Indels

Single nucleotide polymorphisms (SNPs) are the most common type of genetic variation, occurring approximately once every 300 base pairs in the human genome. A SNP is a position where two or more alternative bases are present in at least 1% of the population. In pharmacogenomics, SNPs may occur in coding regions (resulting in amino acid changes or silent mutations), splice sites, promoters, enhancers, or noncoding regulatory regions.

Nonsynonymous SNPs that alter amino acid sequence can change protein function through several mechanisms. A substitution at a catalytically critical residue may abolish enzymatic activity entirely. A substitution at a residue involved in substrate recognition may alter substrate specificity or affinity. A substitution that destabilizes protein folding may lead to accelerated degradation. The CYP2C9*2 and *CYP2C9*3 variants are examples of nonsynonymous SNPs with functional consequences.

Synonymous SNPs, which do not change the amino acid sequence, were historically considered benign. However, evidence now indicates that synonymous variants can affect mRNA splicing, stability, and translation kinetics. The ABCB1 c.3435C>T variant is a well-studied example.

Insertions and deletions (indels) are also clinically relevant. The *CYP2D6*3 allele is a single-base deletion (c.775delA) that causes a frameshift and premature stop codon. This is a classic example of a Frameshift Mutation with complete loss of enzymatic function. Indels in repeat regions can also affect gene expression, as seen in the variable number tandem repeat (VNTR) in the CYP2D6 promoter that influences transcriptional activity.

Copy Number Variations

Copy number variations (CNVs) are structural variants involving the duplication or deletion of genomic segments larger than 1 kilobase. In pharmacogenomics, CNVs are particularly important for CYP2D6, where gene duplication events produce alleles with two, three, or even 13 tandem copies of the gene.

The functional consequence of CYP2D6 duplication is increased enzymatic activity. Patients with duplicated alleles metabolize substrates more rapidly, often requiring higher-than-standard doses to achieve therapeutic concentrations. For codeine, which is activated by CYP2D6 to morphine, ultrarapid metabolizers can experience life-threatening opioid toxicity even at standard doses. The US Food and Drug Administration (FDA) has issued a contraindication for codeine use in children with CYP2D6 ultrarapid metabolizer status.

CNVs in other pharmacogenes are less common but clinically relevant. GSTT1 and GSTM1 deletions are common and affect detoxification of chemotherapy agents. CYP2A6 deletions affect nicotine metabolism and smoking behavior. Detection of CNVs requires methods capable of quantifying gene dosage, such as real-time PCR with copy number assays, multiplex ligation-dependent probe amplification (MLPA), or chromosomal microarray.

Methods Used in Pharmacogenomic Testing

PCR-Based Assays

Polymerase chain reaction (PCR) remains the workhorse of pharmacogenomic testing, particularly for targeted genotyping of known variants. The general approach involves amplifying the genomic region of interest, then detecting the variant allele using one of several strategies.

Allele-specific PCR uses primers designed with their 3' terminal nucleotide complementary to either the wild-type or variant allele. Under optimized conditions, a mismatched 3' terminus is poorly extended by DNA polymerase, allowing allele discrimination based on amplification success. Typical reaction conditions include 10 to 50 ng genomic DNA, 0.2 to 0.5 μM primers, 200 μM each dNTP, 1.5 to 2.5 mM MgCl₂, and 0.5 to 1.25 U thermostable DNA polymerase in a 20 to 50 μL reaction volume. Thermal cycling typically involves 35 to 40 cycles of denaturation at 95°C for 30 seconds, annealing at 55 to 65°C for 30 seconds, and extension at 72°C for 30 seconds.

TaqMan assays use allele-specific probes labeled with distinct fluorophores. Each probe is complementary to either the wild-type or variant allele and carries a quencher. During PCR, the 5' exonuclease activity of Taq polymerase cleaves the probe, separating fluorophore from quencher and generating a fluorescent signal. The ratio of the two fluorophores indicates the genotype. TaqMan assays are highly reproducible, require minimal optimization, and are amenable to high-throughput 384-well formats.

For CYP2D6, the presence of pseudogenes and highly homologous sequences complicates PCR-based genotyping. Long-range PCR using primers specific to the functional gene, followed by nested PCR or sequencing, is often required to avoid co-amplification of the nonfunctional CYP2D7 pseudogene. This technical challenge underscores the importance of assay design in pharmacogenomic testing.

For a detailed discussion of PCR principles and optimization, see PCR Testing.

Microarray and NGS Platforms

Microarray-based genotyping platforms allow simultaneous interrogation of hundreds of thousands of SNPs in a single assay. Commercial pharmacogenomic arrays, such as the DMET Plus array, contain probes for thousands of variants across hundreds of pharmacogenes. The principle involves hybridization of fluorescently labeled fragmented DNA to allele-specific oligonucleotide probes immobilized on a solid surface. Genotype calling is based on the ratio of fluorescence intensities between allele-specific probes.

Microarrays offer several advantages: high throughput, low cost per sample at scale, and the ability to interrogate many genes simultaneously. However, they are limited to detecting known variants and cannot identify novel mutations. Additionally, rare variants not represented on the array will be missed, potentially leading to incorrect phenotype predictions.

Next-generation sequencing (NGS) overcomes this limitation by determining the actual nucleotide sequence of target regions. Targeted pharmacogenomic panels typically sequence the entire coding region, flanking intronic regions, and promoter regions of 10 to 50 pharmacogenes. This approach detects known variants, novel variants, and small indels within the sequenced regions.

NGS workflows involve library preparation (fragmentation, end repair, adapter ligation, and amplification), target enrichment (hybridization capture or amplicon-based), and sequencing on platforms such as Illumina or Ion Torrent. Sequence reads are aligned to the reference genome, and variants are called using bioinformatics pipelines. Coverage of at least 30× is typically required for confident variant calling, though pharmacogenomic panels often achieve 100× to 500× coverage.

A key advantage of NGS is the ability to determine haplotype phase—the arrangement of variants on each chromosome—which is critical for CYP2D6, where multiple variants on the same allele determine the phenotype. However, NGS data analysis is complex and requires specialized bioinformatics expertise. Additionally, CYP2D6 CNV detection from NGS data requires read-depth analysis, which is less straightforward than dedicated copy number assays.

Method	Variants Detected	Throughput	Turnaround Time	Cost per Sample	Key Limitation
Allele-specific PCR	Known SNPs/indels	Low-medium	2-4 hours	Low	Limited multiplexing
TaqMan qPCR	Known SNPs/indels	Medium	2-4 hours	Low	One variant per reaction (or few)
Microarray	Known SNPs/CNVs	High	1-2 days	Medium	Misses novel variants
Sanger sequencing	Known and novel variants	Low	1-2 days	Medium	Limited to short regions
Targeted NGS	Known and novel variants, some CNVs	High	3-7 days	Medium-high	Complex data analysis

Clinical Applications and Guidelines

CPIC Guidelines

The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes peer-reviewed, evidence-based guidelines for using pharmacogenomic test results to guide drug therapy. These guidelines are updated regularly and cover more than 25 gene-drug pairs, including CYP2C19-clopidogrel, CYP2C9/VKORC1-warfarin, TPMT-thiopurines, and HLA-B-abacavir.

CPIC guidelines assign each genotype a predicted phenotype (e.g., poor metabolizer, intermediate metabolizer) and provide specific prescribing recommendations. For example, the CYP2C19-clopidogrel guideline recommends alternative antiplatelet therapy (e.g., prasugrel or ticagrelor) for CYP2C19 poor metabolizers undergoing percutaneous coronary intervention. The guideline assigns levels of evidence and provides dosing recommendations where applicable.

CPIC guidelines are designed to be actionable—they tell clinicians what to do with a test result, not just what the result means. This distinguishes them from other resources that merely describe variant-drug associations. The guidelines are freely accessible and are increasingly integrated into electronic health records with clinical decision support alerts.

Examples in Cardiology and Psychiatry

Warfarin is a classic example of pharmacogenomics-guided dosing. The drug has a narrow therapeutic index, and both bleeding and thrombotic complications are common with incorrect dosing. CYP2C9 variants reduce warfarin clearance, while VKORC1 variants alter the drug's target sensitivity. Together, CYP2C9 and VKORC1 genotyping explains approximately 40% of the variability in warfarin dose requirements.

Pharmacogenomic-guided warfarin dosing algorithms incorporate genotype along with clinical factors such as age, body surface area, and concomitant medications. The International Warfarin Pharmacogenetics Consortium developed an algorithm that estimates the therapeutic dose more accurately than fixed dosing or clinical-only algorithms. However, randomized controlled trials have shown mixed results regarding clinical outcomes, with some trials showing reduced hospitalization and improved time in therapeutic range, while others show no significant benefit.

Clopidogrel is a prodrug requiring bioactivation by CYP2C19. The active metabolite irreversibly inhibits the platelet P2Y12 receptor, preventing platelet aggregation. CYP2C19 poor metabolizers have reduced active metabolite formation and higher rates of major adverse cardiovascular events after stent placement. The FDA added a boxed warning to clopidogrel regarding reduced effectiveness in CYP2C19 poor metabolizers. Genotype-guided antiplatelet therapy, selecting prasugrel or ticagrelor for poor metabolizers, has been shown to reduce thrombotic events in observational studies and some randomized trials.

In psychiatry, CYP2D6 and CYP2C19 genotyping guides antidepressant selection and dosing. Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine and fluoxetine are CYP2D6 substrates. Poor metabolizers have higher plasma concentrations and increased risk of adverse effects, while ultrarapid metabolizers may have subtherapeutic concentrations and poor response. CYP2C19 metabolizes sertraline and citalopram, and genotype-guided dosing has been shown to reduce adverse effects and improve response in some studies.

Evidence and Clinical Utility

Clinical Trials and Studies

The evidence base for pharmacogenomics testing varies substantially across gene-drug pairs. For some, such as HLA-B*57:01 screening before abacavir initiation, the evidence is robust and practice-changing. The PREDICT-1 study randomized 1,956 patients to prospective HLA-B*57:01 screening or standard care. Screening eliminated immunologically confirmed hypersensitivity reactions, reducing the incidence from 2.7% to 0%.

For other gene-drug pairs, evidence is more limited. The Clinical Pharmacogenetics Implementation Consortium uses a standardized grading system to assess the quality of evidence, ranging from high (multiple randomized trials or well-designed observational studies) to low (case reports or small studies). Many guidelines include recommendations based on moderate evidence, acknowledging that randomized trials are not feasible for all gene-drug pairs.

The implementation of pharmacogenomic testing in clinical practice has been studied in several large programs. The Ubiquitous Pharmacogenomics (U-PGx) consortium in Europe is conducting a multicenter, randomized controlled trial of preemptive pharmacogenomic testing across seven European countries. The PREPARE study enrolled more than 7,000 patients and is evaluating the impact of a 12-gene pharmacogenomic panel on adverse drug reactions and hospitalizations.

Cost-Effectiveness

The cost-effectiveness of pharmacogenomics testing depends on the drug, the clinical context, and the healthcare system. For drugs with severe, costly adverse effects, testing is clearly cost-effective. HLA-B*57:01 screening before abacavir is cost-saving because it prevents potentially fatal hypersensitivity reactions and avoids the costs of treating those reactions.

For other applications, cost-effectiveness is more nuanced. CYP2C19 testing before clopidogrel prescription has been shown to be cost-effective in patients undergoing percutaneous coronary intervention, primarily by reducing stent thrombosis and its associated costs. However, the cost-effectiveness varies with the cost of alternative antiplatelet agents and the baseline risk of thrombotic events.

Preemptive pharmacogenomic testing—testing multiple genes before any drug is prescribed—has been proposed as a more efficient strategy than reactive testing. Modeling studies suggest that preemptive testing becomes cost-effective when patients are likely to receive multiple pharmacogenomically relevant drugs over their lifetime. However, the upfront cost of panel testing and the challenge of ensuring that results are available when needed remain barriers to implementation.

Limitations and Challenges

Ethnic Diversity in Allele Frequencies

Pharmacogenomic allele frequencies vary substantially across populations. CYP2C19 poor metabolizer status is present in approximately 2% to 5% of Caucasians but 15% to 25% of East Asians. CYP2D6 ultrarapid metabolizer status is more common in Ethiopians and Saudi Arabians (up to 20%) than in Northern Europeans (1% to 2%). These differences have important clinical implications.

Most pharmacogenomic research has been conducted in populations of European ancestry. Variants that are common in other populations may be underrepresented in databases and guidelines. For example, the *CYP2C9*8, *CYP2C9*11, and *CYP2C9*5 alleles are more common in African populations and reduce enzymatic activity, but they are not included in many genotyping panels.

The lack of diversity in pharmacogenomic research can lead to health disparities. Patients of non-European ancestry may receive genotype results that are incomplete or misinterpreted because the testing platform does not include population-specific variants. Efforts to increase diversity in pharmacogenomic research and to develop population-specific testing panels are ongoing.

Interpretation of Variants of Unknown Significance

Not all genetic variants have known functional consequences. Variants of unknown significance (VUS) are sequence changes for which the effect on protein function is not established. In pharmacogenomic testing, VUS present a clinical challenge: should a patient with a VUS in CYP2D6 be treated as a normal metabolizer, or should the VUS be assumed to affect function?

The conservative approach is to treat VUS as having no effect until evidence suggests otherwise. However, this can lead to incorrect phenotype predictions if the VUS actually reduces function. Conversely, assuming all VUS are deleterious would lead to unnecessary dose reductions and potentially subtherapeutic drug concentrations.

Functional characterization of VUS is an active area of research. In vitro assays using recombinant enzymes can determine the catalytic activity of variant proteins. Computational prediction tools, such as PolyPhen-2 and SIFT, provide in silico predictions of functional impact, but these are not definitive. For clinical decision-making, VUS should be interpreted with caution, and consultation with a clinical pharmacologist or pharmacist with pharmacogenomics expertise is recommended.

Ethical, Legal, and Social Implications

Genetic Privacy

Pharmacogenomic test results are genetic information and are subject to privacy protections. In the United States, the Genetic Information Nondiscrimination Act (GINA) of 2008 prohibits health insurers and employers from using genetic information for discrimination. However, GINA does not apply to life insurance, disability insurance, or long-term care insurance.

The storage and sharing of pharmacogenomic data raise additional privacy concerns. Results are often stored in electronic health records, where they may be accessible to multiple healthcare providers. While this accessibility is necessary for clinical decision-making, it also increases the risk of unauthorized access. Data security measures, including encryption and access controls, are essential.

Patients should be informed about the privacy implications of pharmacogenomic testing before providing consent. This includes information about who will have access to results, how long results will be stored, and the potential for future use of data in research.

Insurance and Employment Concerns

Despite GINA's protections, concerns about genetic discrimination persist. Patients may fear that pharmacogenomic test results could affect their ability to obtain or maintain health insurance or employment. These concerns can deter patients from undergoing testing, even when it would be clinically beneficial.

The distinction between pharmacogenomic testing and other forms of genetic testing is important. Pharmacogenomic results predict drug response, not disease risk. A CYP2D6 poor metabolizer result does not indicate that a patient is at increased risk of developing any disease. However, the public may not understand this distinction, and concerns about discrimination may be based on misconceptions.

Healthcare providers should address these concerns directly, explaining the nature of pharmacogenomic information and the legal protections in place. Patients who remain concerned about privacy may choose to pay out-of-pocket for testing rather than submitting results to insurance, though this limits the integration of results into clinical care.

Common Pitfalls and Best Practices

Misinterpreting Phenotype Predictions

A common error in pharmacogenomics is conflating genotype with phenotype. Genotype refers to the specific alleles present, while phenotype refers to the observed or predicted functional consequence. A patient may carry two loss-of-function CYP2D6 alleles (genotype), but the predicted phenotype depends on the specific alleles and their combined effect.

For example, a patient with one *CYP2D6*4 allele (nonfunctional) and one *CYP2D6*10 allele (reduced function) has a different predicted phenotype than a patient with two *CYP2D6*4 alleles. The former is typically classified as an intermediate metabolizer, while the latter is a poor metabolizer. Misclassification can lead to incorrect dosing recommendations.

Another pitfall is assuming that phenotype predictions are absolute. A poor metabolizer prediction does not mean zero enzyme activity; it means substantially reduced activity. Some residual activity may remain, and clinical factors such as drug-drug interactions can further modulate enzyme function. Phenotype predictions should be interpreted as probabilistic, not deterministic.

Overlooking Drug-Drug Interactions

Pharmacogenomic test results are interpreted in the context of a patient's current medications. A patient with normal CYP2D6 genotype may exhibit poor metabolizer phenotype if they are taking a strong CYP2D6 inhibitor such as paroxetine or fluoxetine. Conversely, a patient with intermediate metabolizer genotype may have near-normal activity if they are taking an enzyme inducer such as rifampin.

Drug-drug interactions can phenocopy genetic variants, leading to unexpected drug responses. Clinicians must consider both genetic and environmental factors when interpreting pharmacogenomic test results. This is particularly important in polypharmacy settings, where multiple medications may affect the same metabolic pathway.

Best practices include reviewing the patient's complete medication list, including over-the-counter drugs and herbal supplements, when interpreting pharmacogenomic results. Clinical decision support systems can integrate pharmacogenomic results with drug-drug interaction checking to provide more accurate recommendations.

Frequently Asked Questions

What is pharmacogenomics testing?

Pharmacogenomics testing is a laboratory analysis that examines specific genetic variants in a patient's DNA to predict how they will respond to certain medications. The results help clinicians select appropriate drugs and doses, reducing the risk of adverse reactions and improving therapeutic efficacy.

How does pharmacogenomics testing work?

A DNA sample is collected, typically from blood, saliva, or a cheek swab. The sample is sent to a laboratory where DNA is extracted and analyzed for specific genetic variants in pharmacogenes. The laboratory report identifies the patient's genotype for each gene tested and provides an interpretation, including predicted phenotype and clinical recommendations.

What genes are commonly tested in pharmacogenomics?

Commonly tested genes include CYP2D6, CYP2C19, CYP2C9, CYP3A4, CYP3A5, VKORC1, TPMT, DPYD, SLCO1B1, and HLA genes such as HLA-B*57:01. The specific genes tested depend on the clinical indication and the testing platform used.

What are the benefits of pharmacogenomics testing?

Benefits include reduced risk of adverse drug reactions, improved drug efficacy, faster achievement of therapeutic doses, and avoidance of ineffective medications. For certain drugs, pharmacogenomic testing can be life-saving, as with HLA-B*57:01 screening before abacavir use.

Are there limitations to pharmacogenomics testing?

Yes. Pharmacogenomics testing does not predict all drug responses. Many drugs are metabolized by multiple enzymes, and genetic variation in one enzyme may be compensated by others. Additionally, non-genetic factors such as age, renal function, and drug-drug interactions significantly affect drug response. Testing also may not detect rare or population-specific variants.

How long does it take to get pharmacogenomic test results?

Turnaround time depends on the testing method and laboratory. Point-of-care tests can provide results in under an hour, while send-out tests typically take 3 to 7 days. Comprehensive NGS-based panels may take 1 to 2 weeks.

Is pharmacogenomics testing covered by insurance?

Coverage varies by insurance provider and the clinical indication. Some insurers cover testing for specific gene-drug pairs with strong evidence, such as HLA-B*57:01 before abacavir. Coverage for panel-based testing is less consistent. Patients should check with their insurance provider before testing.

Can pharmacogenomics testing predict all drug reactions?

No. Pharmacogenomics testing predicts a subset of drug responses where genetic variation has a well-established effect. Many adverse drug reactions are not genetically determined and cannot be predicted by pharmacogenomic testing. Additionally, testing only covers variants included in the assay, and novel or rare variants may be missed.

Key Takeaways

Pharmacogenomics testing analyzes genetic variants in drug-metabolizing enzymes, transporters, and targets to predict drug response and guide prescribing.
CYP2D6, CYP2C19, and CYP2C9 are the most clinically relevant drug-metabolizing enzymes, with variants causing poor, intermediate, normal, or ultrarapid metabolizer phenotypes.
Testing methods range from single-variant PCR assays to comprehensive NGS panels, each with distinct advantages and limitations.
CPIC guidelines provide evidence-based recommendations for using pharmacogenomic test results in clinical practice.
Pharmacogenomic testing has demonstrated clinical utility for drugs such as warfarin, clopidogrel, abacavir, and thiopurines, but evidence varies across gene-drug pairs.
Limitations include incomplete coverage of population-specific variants, challenges in interpreting variants of unknown significance, and the influence of non-genetic factors on drug response.
Ethical considerations include genetic privacy, potential discrimination, and the need for informed consent and patient education.